Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 ...
Sue McCarthy shares her experience overcoming stage 3B lung cancer, reflecting on the impact of her diagnosis. After ...
Confirmation of 30mg efti as optimal biological dose relevant for Immutep’s oncology pipeline and potential future Biological ...
Trodelvy is being investigated for use in other TNBC and HR+/HER2- breast cancer populations, as well as a range of tumor types where Trop-2 is highly expressed, including extensive-stage small cell ...
In the histology-centric world of cancer medicine, further work is needed to increase genomic testing rates and educate ...
Summit Therapeutics Inc. (NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer ...
"ESMO 2025: Anticipated Phase II data debut for Eikon’s NSCLC candidate" was originally created and published by Clinical ...
Wall Street analysts expect the subcutaneous version of Keytruda, which just launched last week, to help soften the blow when ...
Zacks Investment Research on MSN
Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?
Merck’s MRK shares have risen almost 13% in the past week as Pfizer’s PFE landmark deal with the Trump administration to ...
Positive opinion also granted for KEYTRUDA as part of a perioperative regimen for the treatment of certain adult patients with resectable locally advanced head and neck squamous cell carcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback